Table 2 Parameters of hemostasis, rheology, fibrinolysis, platelet activation and extent and severity of coronary atherosclerosis
| Â | all patients | Diabetes mellitus Typ II | control patients | p-value |
|---|---|---|---|---|
| Â | (n = 150) | (n = 26) | (n = 122) | Â |
hemostasis | ||||
fibrinogen (mg/dl) | 282 ± 64 | 295 ± 76 | 278 ± 61 | 0.1618 |
prothrombinfragment 1 + 2 (μg/dl) | 0,99 ± 0,52 | 1,01 ± 0,55 | 0,87 ± 0,37 | 0.0622 |
D-Dimere (μg/l) | 35 ± 62 | 31 ± 43 | 36 ± 65 | 0.5519 |
Thrombin-Antithrombin-Komplex (μg/l) | 7,6 ± 16 | 9,6 ± 18,7 | 7,3 ± 15,5 | 0.5221 |
Rheology | ||||
plasma viscosity (mPas) | 1,30 ± 0,09 | 1,33 ± 0,09 | 1,29 ± 0,09 | 0.0933 |
erythocyte aggregation M (E) | 6,3 ± 1,8 | 7,3 ± 1,9 | 6,1 ± 1,8 | 0.0026 |
erythocyte aggregation M1 (E) | 11,3 ± 2,5 | 12,8 ± 2,7 | 11,0 ± 2,3 | 0.0013 |
hematocrit (%) | 43,5 ± 3,1 | 42,7 ± 3,7 | 43,6 ± 2,9 | 0.1537 |
fibrinolysis | ||||
tissue-plasminogenaktivator (ng/dl) | 13,47 ± 3,68 | 14,18 ± 3,36 | 13,30 ± 3,77 | 0.4394 |
plasminogenactivatorinhibitor (U/ml) | 5,78 ± 3,25 | 7,36 ± 3,24 | 5,45 ± 3,18 | 0.0017 |
plasmin-α2-antiplasmin-complex (μg/dl) | 395 ± 152 | 378 ± 168 | 396 ± 146 | 0.4245 |
platelet activation | ||||
platelet count (100.000/ml) | 246 ± 71 | 265 ± 71 | 242 ± 71 | 0.1727 |
von Willebrand-factor (μg/l) | 94 ± 31 | 99 ± 32 | 93 ± 30 | 0.3661 |
plateletfactor 4 (μg/l) | 12,7 ± 18,8 | 9,2 ± 10,9 | 13,4 ± 20,1 | 0.9104 |
β-thromboglobulin (μg/l) | 36,68 ± 41,90 | 30,07 ± 17,57 | 38,28 ± 45,53 | 0.7181 |
GMP 140 (μg/l) | 96,36 ± 44,69 | 94,64 ± 23,41 | 96,88 ± 48,26 | 0.2773 |
Extent and severity of coronary atherosclerosis | ||||
total score | 1,451 ± 0,591 | 1,858 ± 0,680 | 1,379 ± 0,550 | 0.0182 |
proximal score | 1,399 ± 0,696 | 1,775 ± 1,037 | 1,333 ± 0,607 | 0.2363 |
distal score | 1,457 ± 0,666 | 1,874 ± 0,647 | 1,388 ± 0,651 | 0.0109 |
1-vessel CAD | 31.0% | 12.0% | 35.0% | Â |
2-vessel CAD | 37.0% | 39.0% | 37.0% | Â |
3-vessel CAD | 32.0% | 50.0% | 28.0% | 0.0306 |